It would be ridiculous to NOT include the vendor and "advisor" shares that are escrowed if you are trying to value this.... They are the ones laughing right now.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%